Research programme: autologous T cell therapies - TxCell

Drug Profile

Research programme: autologous T cell therapies - TxCell

Alternative Names: Ag-Treg therapeutics - TxCell; Balancell; CAR engineered CD4+ Treg cells - TxCell; CAR-Treg-TxCell; CellArthrix; Col-Treg-TxCell; ENTX-BP; ENTX-LN; ENTX-MS; ENTX-SOT; HSP60-Treg-TxCell; Myelin-Treg-TxCell; Tr1 cell therapy - TxCell; TX-MSD

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ospedale San Raffaele; University of British Columbia; University of Lubeck; Weizmann Institute of Science
  • Class CAR-T cell therapies; Cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune-mediated uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bullous pemphigoid; Immune-mediated uveitis; Transplant rejection
  • Research Lupus nephritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 01 Oct 2016 TxCell and the University of British Columbia enter into collaboration to develop CAR-Treg-based cellular immunotherapy for Transplant rejection (TxCell website, March 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (IV)
  • 01 Jun 2016 TxCell and Lubek Institute of Experimental Dermatology, of the University of Lubeck enter into collaboration to develop CAR-Treg-based cellular immunotherapy for Bullous Pemphigoid
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top